Skip to main content

Carevive Advanced NSCLC Oncology Care Model Symposium at Jefferson University

By August 24, 2016February 27th, 2017No Comments
The Oncology care model: Integrating the 13 Point IOM care management care plan for patients with Advanced NSCLC

The Oncology Care Model: Integrating the 13 Point IOM Care Management Plan for Patients With Advanced NSCLC

Wednesday, October 26, 2016
8 am – 12 noon
Solis Cohen Auditorium
Thomas Jefferson University Hospital
Philadelphia, PA

Download Symposium Slides
Download PDF Invite

13 point care management plans … 12 Key Performance Indicators… Improving navigation, care coordination, & guideline-adherent care… Reducing ED visits and hospitalizations and improving palliative care uptake…

Do the new requirements of OCM and other value-based cancer delivery models leave you overwhelmed about where and how to start?

If so, then join us for a CME/CNE-Certified Symposium Featuring Key Experts in NSCLC as they discuss:

  • How OCM and value-based care models are transforming cancer care delivery in lung cancer
  • What are the evolving evidence-based approaches for personalized medical therapeutics in advanced NSCLC
  • How to promote patient-centered, shared decision-making across the lung cancer continuum
  • Implementing highly personalized care management plans with advanced NSCLC patients

Non-small cell lung cancer (NSCLC) accounts for about 27% of all cancer deaths and is by far the leading cause of cancer death among both men and women. Despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, however, there is renewed optimism that these trends have started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among NSCLC scientists and expert clinicians. In addition, there are tremendous pressures on cancer centers and their oncology providers to quantifiably demonstrate value in the care delivered to their patients.

To support oncology providers in the era of value-based cancer care, Carevive Systems has worked with over 1,000 oncology experts to develop workflow and patient engagement tools that support the implementation of established oncology quality measurement programs and will aggregate longitudinal data tracking patients cared for under such delivery models.

Providers from centers who were awarded the Oncology Care Model (OCM) will participate in a Mid-Atlantic, half-day, CME-accredited live symposium with NSCLC expert faculty to discuss the NSCLC treatment landscape and evolving principles and models of value-based care delivery in lung cancer care. Invitations are extended to all NSCLC providers to participate. Topics include a review of current evidence, case studies, and the intersection of quality measures, clinical NSCLC care, and strategies to implement the Oncology Care Model Care Plan.


Benjamin Levy, MD
Mt. Sinai Medical Center


Mark Kris, MD
Memorial Sloan-Kettering Cancer Center

Ajeet Gajra, MD
Upstate Medical University

Avnish Bhatia, MD
Thomas Jefferson University Hospital

Ralph Zinner, MD
Thomas Jefferson University Hospital

Who Should Attend?

The target audiences for these activities are medical oncologists, pulmonologists, pathologists, physician assistants, nurse practitioners, oncology nurses, nurse navigators, palliative/symptom management teams who care for patients with NSCLC and quality administrators responsible for their cancer center’s adherence to value-based care delivery models.


8:00 – 8:30 am Registration & Continental Breakfast
8:30 – 9:00 am Introduction: Value-Based Care in Lung Cancer Avnish Bhatia, MD
Ralph Zinner, MD
9:00 – 10:00 am 1. Variants of EGFR Tumor Mutations and Implications
for the First-Line Management of Metastatic Disease
2. Management of Progressive EGFR Mutation Positive Disease
Mark G. Kris, MD
10:00 – 10:30 am Current and Emerging Evidence for ALK/ROS1-Positive Disease Ralph Zinner, MD
10:30 – 11:00 am 1. The Current and Emerging Role of Immunotherapies for Metastatic NSCLC

2. Other Potentially Targetable Tumor Mutations (BRAF V600E, HER2, RET) for Metastatic NSCLC

Benjamin Levy, MD (Chair)
11:00 – 11:30 am Determining Treatment of the Older Adult with Advanced NSCLC Ajeet Gajra, MD
11:30 am – 12:00 noon Expert Panel & Audience Discussion: How to help team members develop IOM Care Management Plans Benjamin Levy, MD

This activity is supported by an independent educational grant from Genentech BioOncology.

This activity has been approved for 3.5 AMA PRA Category 1 Credit(s)™.

This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.

Designated for 2.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems Inc.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.